We have all seen movies where right before the hero starts fighting, he cracks his knuckles and makes it look like the coolest thing in the world! But then our parents told us that you should not crack your knuckles because that weakens your grip and hand strength. But is that true? While many people do say that they experience a small loss in strength immediately after they crack their knuckles, but are their long-term effects to it? And what is the sound actually coming from?

The reason why people crack their fingers is because the evident and sharp crack noise causes a sense of relief. Many people also do it when they have done an activity that required them to work with their hands a lot like typing or sewing, giving themselves a sense of satisfaction, similar to stretching after doing hard work. That "crack" sound can make some people cringe, while others find it strangely satisfying. Cracking your knuckles is a pretty common habit, but there are a lot of misunderstandings about it. Some people do it without even thinking, others can't stand the noise, and some can't crack their knuckles at all. You might have been told as a kid that it causes arthritis or makes your fingers swell up. But those are just old wives' tales. There's a real science behind this habit, and it's more interesting than you may think.

Why Do Knuckles Make That Popping Sound?

The "crack" isn't actually bones breaking or anything bad happening to your joints. It's a normal thing called "crepitus." This just means harmless popping, snapping, or grinding sounds that come from your joints. The main reason you hear this sound is because of gas bubbles in the fluid that cushions your joints. This fluid is called synovial fluid. When you move or stretch, these tiny bubbles form and then pop, making the sound. It's totally normal and doesn't hurt you. Sometimes, especially in bigger joints like your knees, shoulders, or ankles, the sound can also happen when the stretchy tissues that connect your bones (ligaments and tendons) move slightly and then snap back into place.

After you crack your knuckles, you can't usually do it again right away. You have to wait a bit. That's because the gas bubbles in your joint fluid have already popped, and it takes a little while for them to build up again. While cracking your knuckles doesn't give you arthritis, doing it too much might cause some problems. Doctors say that cracking them too often could make your joints a little wobbly and might even make your grip weaker. Also, if the stretchy tissues in your joints keep snapping over your bones, they can get irritated and sore.

When Joint Popping Might Mean Something More

Sometimes, a pop in your joint is just like cracking your knuckles, nothing to worry about. But other times, it can be a sign of something else. As we get older, the cushiony stuff in our joints, called cartilage, can start to wear down. This cartilage helps your bones move smoothly. When it gets thin or uneven, the bones can rub together, and that can make a grinding or popping sound. This is different from the pop you get from gas bubbles. If this grinding sound happens along with pain, it could be a sign of osteoarthritis. This is a type of joint problem that's more common in older people, but younger people can get it too, especially after a joint injury. If your joints hurt, especially in the morning or after you've been sitting still for a while, feel wobbly, or are hard to move, it's a good idea to see a doctor.

The risk of hantavirus spreading is generally considered low, as repeatedly stated by the World Health Organization (WHO) and other global health agencies, after the recent outbreak on the MV Hondius cruise ship. However, a shocking peer-reviewed study has found that the Andes strain of the rat-borne virus can persist in human semen for up to six years.

More concerning is the possibility that the virus could potentially be transmitted sexually even after a person has recovered, according to the 2023 study published in the journal Viruses.

The research, conducted by Swiss scientists at Spiez Laboratory, suggests that hantavirus may survive in the male reproductive tract like viruses such as Ebola.

What Did The Study Find?

The research team, which included scientists from the University of Bern and the University of Lausanne, investigated a 55-year-old man who had contracted the Andes strain of hantavirus in South America six years earlier.

The researchers discovered that although the virus was no longer detectable in the man’s blood, urine, or respiratory tract, it was still present in his semen 71 months later.

"Viral RNA remained primarily detectable intracellularly in semen samples throughout the complete study period of almost six years," the 2023 study stated,

“Taken together, our results show that the Andes virus has the potential for sexual transmission,” it added. However, so far no confirmed case of such transmission has yet been documented.

Also read: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support

Andes Virus: Male Testes Hidden ‘Reservoirs’?

Hantavirus is not the first virus found to persist in the male reproductive system. According to the study, viruses such as Ebola and Zika are also known to evade the immune system by remaining hidden in the testes for extended periods.

A 2021 Ebola outbreak in Guinea, which resulted in 23 cases and 12 deaths, was later linked to a survivor of the 2014–2016 West Africa epidemic who reportedly transmitted the virus sexually years after recovery.

The testes are considered a biological “safe harbour” for at least 27 infectious diseases, enabling certain pathogens to remain hidden in the body and potentially spread years after a patient has recovered.

Because sperm cells are essential for reproduction, they are shielded from the body’s immune response. However, this immune protection can also create an environment where viruses are able to survive and persist for long periods.

Safe-Sex Guidance For Hantavirus-Infected Individuals

Analysts at Airfinity, a company that tracks global health risks, recommend that male patients should receive “extensive safe-sex guidance beyond the [42-day] quarantine”, the Telegraph reported

The guidance should be “analogous to the World Health Organization’s (WHO) Ebola survivor semen-monitoring protocols,” it added.

The WHO protocols recommend that the semen of male Ebola survivors should be tested every three months and should not be considered virus-free until two consecutive negative test results are obtained.

Until cleared, they should “abstain from all types of sex” or “use condoms consistently and correctly.”

They should also wash themselves “thoroughly” with soap and water after any contact with semen – including after masturbation, according to the guidance.

Hantavirus on MV Hondius

According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.

A Dutch couple is believed to have been first exposed to the virus while visiting a birdwatching site in Argentina.

The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.

While all passengers onboard the cruise have been taken care of by health authorities, the virus' long incubation period is a serious risk factor. Which means that even those asymptomatic can turn infectious 6-8 weeks later.

While GLP-1 weight-loss drugs such as Wegovy and Mounjaro have helped patients lose weight, a major concern has been weight regain once the therapy is stopped. Now, a new study by US scientists suggests that a daily pill may help prevent that rebound weight gain.

According to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian, switching to the once-daily orforglipron pill may not only help maintain weight loss but also preserve cardiometabolic benefits.

Orforglipron is US drugmaker Eli Lilly’s first oral pill for weight loss, marketed as Foundayo. In April, it received approval from the US Food and Drug Administration (FDA).

Weight Loss With Daily Pill Orforglipron

In the Eli Lilly-funded trial, published in the journal Nature Medicine, researchers found that patients in the Phase 3b clinical trial maintained around 75–80 per cent of their weight loss. They also experienced several additional health benefits, including:

• Reduced waist circumference
• Improved blood pressure
• Better blood sugar control
• Lower triglyceride levels
• Improved cholesterol levels

The Clinical Trial

The ATTAIN-MAINTAIN trial enrolled patients who had already achieved substantial weight loss that later plateaued while taking weekly injectable GLP-1 drugs during the SURMOUNT-5 trial.

The study randomized:

• 205 patients taking tirzepatide
• 171 patients taking semaglutide

The results showed that patients switching from tirzepatide to orforglipron maintained an average of 74.7 per cent of their body weight reduction, compared with 49.2 per cent in the placebo group.

Meanwhile, patients who switched from semaglutide to orforglipron maintained 79.3 per cent of their body weight reduction, compared with 37.6 per cent in the placebo arm.

Over the 52-week trial period, participants treated with orforglipron gained:

• An average of 5 kg (11 lbs) in the tirzepatide group
• An average of 1 kg (2.2 lbs) in the semaglutide group

How The Daily Pill Orforglipron Works

Eli Lilly licensed orforglipron, the active ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.

Like injectable GLP-1 drugs, Orforglipron is available in six doses ranging from 0.8 mg to 17.2 mg. Patients typically begin at the lowest dose and gradually increase under medical supervision.

Also read: Donald Trump Will Have Fourth Medical Checkup In May, Says White House

Unlike some oral GLP-1 drugs, people taking orforglipron do not need to restrict food or drink intake after taking the pill. Researchers say the small molecule is absorbed quickly into the bloodstream and reaches target tissues efficiently.

Orforglipron: Side Effects And Safety Concerns

Foundayo is not approved for use in children and carries warnings about potential thyroid tumours, including thyroid cancer.

The drugmaker advises patients to watch for symptoms such as:

• Lump or swelling in the neck
• Hoarseness
• Trouble swallowing
• Shortness of breath

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Stomach pain
• Headache
• Swollen belly
• Fatigue
• Belching
• Heartburn
• Gas
• Hair loss.

In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.

While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.

The seven-minute injectable immunotherapy has the potential to:

• Treat up to five patients in the time taken to treat one patient through intravenous infusion
• Help optimise healthcare resources
• Lower indirect treatment costs
• Minimise the need for patients to travel long distances
• Reduce the amount of time caregivers spend in hospitals

“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.

What Is Tecentriq SC? What's The Cost In India?

Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.

First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.

In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.

According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".

Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

How Does Tecentriq SC Work?

Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.

The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.

How Tecentriq SC will Boost Cancer Care In India

The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.

“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.

Read More: India Better Prepared For Hantavirus Outbreaks After COVID-19 Experience, Says Dr NK Ganguly | Exclusive

Tecentriq SC: Safety

Global studies have indicated strong patient preference for subcutaneous administration.

According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:

• Four out of five patients preferred Tecentriq SC over IV administration
• Patients cited less time in clinics, greater comfort, and lower emotional distress as key reasons for preference

Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.

In the IMscin001 study presented at ESMO 2023:

• 90 per cent of healthcare professionals agreed the SC formulation was easy to administer
• 75 per cent believed it could save time for healthcare teams.